Circulating P3NP and Cardiovascular Events in Hemodialysis Patients

Toujinkai Hospital

Status: Completed

Conditions: Cardiovascular Events; Cardiac Fibrosis

Study type: Observational

Funder types: Other

Identifiers

NCT03391128

P3NPhemodialysis

Details and patient eligibility

About

This study evaluates whether circulating levels of aminoterminal propeptide of type III procollagen (PIIINP) can predict the cardiovascular events in hemodialysis patients.

Full description

Type III collagen abundantly exists in the cardiovascular system including the aorta and heart. The aminoterminal propeptide of type III procollagen (PIIINP) is an extension peptide of type III procollagen, which is cleaved off stoichiometrically during conversion from type III procollagen to type III collagen and liberated to serum. Elevated serum concentrations of PIIINP are considered a marker of higher collagen turnover and tissue fibrosis including the heart and vascular system. In this study, the investigators prospectively examined whether serum levels of PIIINP could be a biomarker for predicting cardiovascular events in hemodialysis patients.

Enrollment: 244 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• End-stage kidney disease patients who had been undergoing maintenance hemodialysis over one year in Toujinkai Hospital at the point of January 1, 2005

Exclusion criteria

• Histories of coronary events and/or interventions
• Congestive heart failure of New York Heart Association grades III to IV
• Moderate or worse valvular heart disease
• Permanent pacemaker implantation
• Idiopathic cardiomyopathy
• Chronic obstructive pulmonary disease
• Malignancy
• Acute hepatitis, chronic hepatitis, or liver cirrhosis including carrier of hepatitis virus